Workflow
Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment

Benitec Biopharma Inc. (NASDAQ:BNTC) is one of the best breakout stocks to invest in. On November 4, an analyst at Citizens JMP raised the stock’s price target to 22from22 from 20 while reiterating an Outperform rating. The price target hike follows topline clinical data results that showed a 100% response rate for BB-301 in Phase 1b/2a of the treatment for Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic muscle-wasting disease. Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Res ...